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Blood level monitoring helps to determine the therapeutic and toxic ranges for anticonvulsants and antidepressants. We 
investigated initial drug-drug interactions between lamotrigine and sertraline. We report on case histories of two epileptic 
patients who were initially on lamotrigine and to whom sertraline was added to control psychiatric features. In case 1, a 
total daily dose of 25 mg sertraline, with nondetectable s rtraline and desmethylsertraline blood levels, resulted in a doubling 
of the lamotrigine blood level with symptoms of toxicity. In case 2, a 25 mg reduction in the total daily dose of sertraline 
resulted in halving of the lamotrigine blood level even though the lamotrigine dosage was increased by 33%. This shows that 
sertraline has potent interactions with lamotrigine metabolism. The authors hypothesize that inhibition of glucuronidation 
is responsible. Clinicians are advised to observe for symptoms of toxicity and to do serial blood levels to monitor this 
interaction. 
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INTRODUCTION 
The combined use of antidepressants and anticonvul- 
sants is of growing concern as increasing pharmaceu- 
tical agents are released with increased indications. 
Antidepressants are utilized in the epilepsy popula- 
tion to treat affective disorders, schizoaffective disor- 
ders, obsessive compulsive disorders and intermittent 
explosive disorders 1'2. A growing list of anticonvul- 
sants is being utilized to treat bipolar and schizoaf- 
fective disorders in conjunction with antidepressants 
and neuroleptics 3'4. 
In the past, the greatest concern was the effect of the 
psychotropic upon seizure threshold. Although drug- 
drug interactions have been considered, these usually 
focused upon agents within one therapeutic family--  
anticonvulsant interactions or psychotropic interac- 
tions. The potential for toxic interactions among an- 
tidepressants and anticonvulsants has not been widely 
appreciated. 
Within the past decade, a series of serotonergic spe- 
cific re-uptake inhibitors (SSRIs) have been released. 
Some of these SSRIs are noted to have potent cy- 
tochrome P450 inhibition with expected drug-drug 
interactions 5. Two cases are described wherein the 
epileptic patient had been maintained on lamotrigine 
and with the addition of sertraline toxic effects with 
increased blood levels were noted (Table l). 
CASE1 
RH is a 39 year old single white female who de- 
veloped post-traumatic epilepsy with cluster seizures 
which had relatively poor response to phenobarbital, 
carbamazepine, f lbamate, and valproic acid. The pa- 
tient had been maintained on lamotrigine 200 mg to- 
tal daily dose when initially evaluated in psychiatric 
consultation. The baseline lamotrigine blood level 
was 2.5 /zg/ml. The patient was diagnosed as hav- 
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Table 1 : Lamotrigine-sertraline interactions. 
Lamotrigine dose Lamotrigine blood level Sertraline dose Sertraline blood level Desmethylsertraline b ood level 
Case 1 200 mg 2.5 #g/ml 0 mg 0 0 
200 mg 5.1 /~g/ml 25 mg nd nd 
100 mg 3.1 /zg/ml 50 mg nd nd 
Case 2 600 mg 19.3 #g/ml 75 mg nd 24.0 ng/ml 
800 mg 9.8/.tg/ml 50 mg nd nd 
nd = nondetectable. 
ing post-traumatic ntermittent explosive disorder 6. 
A total daily dose of 25 mg of sertraline was pre- 
scribed. Although the patient's irritability began to 
diminish, she complained of increasing confusion and 
cognitive impairment. A significant increase in lam- 
otrigine blood level (5.1 /zg/ml) was noted 6 weeks 
following the addition of sertraline. Thereafter, the 
patient's ertraline was increased to 50 mg daily with 
total control of explosive features to a point where 
the patient commented that she had returned to her 
pre-accident psychiatric baseline. At the same time, 
the patient's lamotrigine was decreased to 100 mg 
daily. On this lower lamotrigine dosage, the patient's 
confusion and impaired cognition cleared within 3 
weeks. Even though the lamotrigine was only half of 
what had been initially prescribed, the blood level re- 
mained higher (3.1 #g/ml) with significant reduction 
in her cluster seizures. 
CASE 2 
MH is a 17 year old single white female with a mixed 
epileptic disorder including petit mal, grand mal, and 
complex partial seizures with secondary generaliza- 
tion which had an incomplete response to phenobar- 
bital, phenytoin, valproic acid, and felbamate. At the 
time of the initial psychiatric onsultation, the pa- 
tient had been maintained on a total daily dose of 
450 mg of lamotrigine with incomplete control of 
seizures. The patient's psychiatric history included 
three admissions, multiple suicide attempts, complete 
vegetative-affective cluster, oppositional defiant be- 
haviour, explosivity with poor impulse control, and 
questionable attention deficit disorder. When seen in 
psychiatric onsultation, the patient was diagnosed 
as having an organic mood disorder secondary to 
epilepsy, intermittent explosive disorder, and conduct 
disorder 6. Historically the patient's affective symp- 
toms had shown some stabilization with valproic acid. 
The patient underwent a lithium trial of 600 mg daily 
with a decrease in explosivity and mood swings. De- 
creased memory, imbalance and tremors were noted 
which necessitated iscontinuation of the lithium. 
Sertraline was initiated and titrated to 75 mg daily 
with decreased severity of affective symptoms and ex- 
plosivity. No side effects were noted. After being on 
sertraline for 6 weeks, the lamotrigine was increased 
to 600 mg daily with decreased seizure frequency. 
On this combined regimen, the patient's behaviour 
was markedly improved with no violent or explo- 
sive episodes. Six weeks after the lamotrigine dosage 
had been increased, the patient complained of marked 
sedation, fatigue, and decreased cognition. The lam- 
otrigine blood level was 19.3 /zg/ml, the sertraline 
blood level was nondetectable, and the desmethylser- 
traline blood level was 24.0 ng/ml. It was felt that 
a drug-drug interaction similar to the previous case 
had occurred and the desire was to minimize toxic- 
ity yet to maintain a lamotrigine blood level higher 
than what would have occurred at the initiation of 
therapy when the patient's eizures were not totally 
controlled. Therefore, the lamotrigine dosage was in- 
creased to 800 mg daily and the sertraline dosage 
was decreased to 50 mg daily. After 2.5 weeks on 
this new regime, the patient had continued seizure 
control, no explosivity, decreased sedation, decreased 
fatigue, and clearer cognition. The repeat lamotrig- 
ine blood level was 9.8 ~zg/ml with sertraline and 
desmethylsertraline blood levels both nondetectable. 
With a 33% reduction in the sertraline daily dose, the 
lamotrigine blood level decreased by approximately 
50%, even though the lamotrigine daily dose had been 
increased by 33%. 
DISCUSSION 
The drug--drug interaction oted in these two cases 
is most striking. In both, toxic symptoms occurred 
with fatigue, sedation, confusion and decreased cog- 
nition as principal symptoms. These symptoms were 
resolved with reduced sertraline dosage and concomi- 
tant decreased lamotrigine blood levels. As sertraline 
is an inhibitor of cytochrome P450 isoenzymes, espe- 
cially IID6, it was expected that the interaction would 
be through such a mechanism. However, lamotrigine 
is primarily metabolized through glucuronidation 7. 
The metabolic pathways for sertraline include N- 
demethylation, hydroxylation, oxidative deamination, 
and glucuronidation 8. Similar to the valproic acid 
inhibition of lamotrigine metabolism, it is hypothe- 
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sized that sertraline reduces lamotrigine glucuronida- 
tion through competitive inhibition with resultant in- 
creased blood levels 9. Another potential mechanism 
would be the direct inhibition of other metabolic pro- 
cesses. 
It is clear that further clinical research on the in- 
teractions between these two drugs is indicated. Until 
it can be clearly established which mechanism exists, 
the authors recommend caution when prescribing ser- 
traline or other SSRIs with lamotrigine. Appropriate 
therapeutic drug monitoring is necessary and should 
prevent any unnecessary toxicity. The authors fur- 
ther recommend that any agent which has a metabolic 
pathway including glucuronidation could result in in- 
creased lamotrigine blood levels, toxicity, and poten- 
tially an increased risk for fatal lamotrigine rashes 
(especially during the first 6 months of lamotrigine 
therapy)l°-12. 
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